Why the Painchek (ASX:PCK) share price is charging 13% higher

The PainChek Ltd (ASX: PCK) share price is soaring today after the app developer received TGA approval for its latest development.

| More on:
A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The PainChek Ltd (ASX: PCK) share price is soaring today after the company announced it has received approvals for its latest pain monitoring app update.

At the time of writing, the mobile medical app developer's shares are up 13% to 7.8 cents per share.

What did Painchek announce?

The Painchek share price is moving after it provided an update this morning noting the company had received CE Mark and Therapeutic Goods Administration (TGA) clearance for its expanded Universal Pain Assessment Solution, or 'Universal' application.

According to the release, these clearances will allow the app to be marketed and sold across Europe, the UK, Australia, Canada, Singapore, and New Zealand.

The new 'Universal' Painchek app builds upon the company's existing pain monitoring technology to now allow all patients to be assessed. Previously the app was specifically for people with dementia.

With the latest approval, the company's market will substantially broaden. The total market for pain monitoring is far larger than the niche market solely serving people with dementia.

What the Universal app adds

Painchek's Universal app implements the widely established self-reporting standard known as the numeric rating scale (NRS). The company's existing technology caters to carers for assessing and managing pain levels for patients who cannot verbalise it. However, with the addition of NSR, carers will now also be able to better support those who can self-report.

Painchek CEO Philip Daffas commented on the approval:

Historically, PainChek and NRS have been separate pain assessment processes in terms of function and documentation, as we initially developed PainChek to be used in situations where patients could not reliably verbalise their pain.

We have now improved the process by incorporating the NRS into the PainChek app, combining the benefits of the two pain scales into one universal pain assessment and management solution.

The initial rollout of the Universal app is slated for Australia and the United Kingdom from April. After which, it will continue to be distributed to mainland Europe and other international markets.

Painchek share price checkup

Considering the 52-week range on the Painchek share price, it has been a wild year for Painchek shareholders. Before today, the share had been floating around its 52-week low of 6.2 cents. Whereas, in May last year, the share price hit a high of 18 cents. 

Despite the increased volatility, the shares have returned a meagre 4% to holders over the past 12 months. For comparison, the S&P/ASX 200 Index (ASX: XJO) has notched up a 28% gain before dividends. 

Motley Fool contributor Mitchell Lawler has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A woman with a sad face looks to be receiving bad news on her phone as she holds it in her hands and looks down at it.
Earnings Results

Nanosonics share price crashes 14% on first-half profit crunch

Investors haven't responded positively to the release of the company's half-year results.

Read more »

Three excited business people cheer around a laptop in the office
Healthcare Shares

Here's why ResMed shares can jump a further 20%

Investors have done very well from this stock recently. The good news is that analysts expect the trend to continue.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Share Gainers

If you'd put $20,000 in this ASX healthcare stock during COVID-19, you'd have $257,000 now

You could have become filthy rich in just 4 years. Just think about that.

Read more »

Shot of a young scientist using a laptop while conducting research in a laboratory.
Healthcare Shares

Sonic Healthcare shares hit 52-week low as analysts take a scalpel to targets

Analysts have sharpened the knives after the latest blood-sucking half year at Sonic Healthcare.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
52-Week Highs

Medibank share price hits 52-week high on US tech partnership

This private health insurer's shares are scaling new heights today. But why?

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

What is the dividend growth rate of CSL stock?

CSL's dividends are worth more than what meets the eye.

Read more »

Shot of a young scientist looking stressed out while working on a computer in a lab.
Earnings Results

Sonic share price sinks after first-half profit crash

The healthcare company's profits have almost halved.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

The market is placing 'zero value' on this ASX 200 stock's booming pipeline

Up 78% in a year, these experts reckon there’s more outperformance to come from this top ASX 200 stock.

Read more »